InnoCare’s oral TYK2 inhibitor fadeucravacitinib meets primary endpoint in phase 3 psoriasis trial

InnoCare Pharma announced that its oral TYK2 inhibitor fadeucravacitinib (also known as ICP-488) achieved the primary endpoint in a phase 3 study of adults with moderate-to-severe plaque psoriasis.

The double‑blind, randomized trial compared fadeucravacitinib with placebo in Chinese patients, showing a clinically meaningful improvement and meeting multiple secondary endpoints. The company said the safety profile was favorable, though detailed efficacy and safety data were not disclosed.

In October 2024, InnoCare reported phase 2 results in which roughly 77‑78% of patients achieved at least a 75% improvement on the Psoriasis Area and Severity Index versus 11.6% with placebo, results comparable to those seen with Bristol Myers Squibb’s oral TYK2 inhibitor Sotyktu.

Psoriasis affects about 125 million people worldwide, and the positive phase 3 data could position fadeucravacitinib as a new oral treatment option pending further regulatory review.